Life Science Strategy and M&A Resources

Independent talent provide an agile source of critical skills that allow life science leaders to keep pace in a fast-changing environment.

An F200 pharma company wanted to implement next generation digital health technologies, which required a thorough review of the existing strategy across three therapeutic areas and a roadmap for...

Pursuing growth into personalized medicine and safer, more effective drug therapy, an F200 biopharmaceutical company wanted to improve its cross-functional end-to-end control strategy and tactics...

A global nonprofit was developing new initiatives focused on building pharmacovigilance systems and regulatory capacity in low and middle-income countries (LMICs). As more pharmaceutical products...

The Director of Product and Portfolio Management at a F200 biopharmaceutical company needed to replace a team of Big Three consultants who had begun working on the integration of a recent...

Innovation expert Steve Wunker joins BTG's Leah Hoffmann to discuss how companies can adapt business strategies to the coronavirus (COVID-19) pandemic and all the upheaval that it has brought.

The head of M&A at a global pharma company was evaluating an acquisition target based in India. His team had already assessed the company’s core business, but it needed help understanding the...

Innovation is typically seen as a way to boost revenues, but it can also be used to cut costs. Expert Stephen Wunker explains.

Johnson & Johnson procurement head George Post talks about building the company's on-demand talent program, Specialists on Demand. Read or listen.

Daniel Lee, who created Pfizer's Consulting and Execution Group, or PCE, shares best practices for building a successful internal consulting group.

Pfizer executive Tim Hylan speaks to us about why he works with freelance pharma consultants.

There's often more focus on the strategic planning process than on actual strategic thought. Create more effective plans with this comprehensive guide.

A VP at a major biopharma company was interested in defining his strategy in the neuroscience space. Looking for a more targeted way to assess the opportunity than big consulting firms could...